Biogut Technologies Inc. is at the forefront of pioneering research and development in diagnostic tools and therapeutics for addressing inflammatory bowel disease (IBD) and associated fibrosis. Leveraging cutting-edge advancements in microbiome science, our company focuses on understanding the intricate role of microbial metabolite receptors in the pathogenesis of IBD and fibrosis.

Our multidisciplinary team of scientists, clinicians, and biotech experts is dedicated to developing groundbreaking solutions aimed at early detection, precise diagnosis, and targeted treatment strategies for patients suffering from IBD fibrosis. By unravelling the complex interactions between gut microbiota and host metabolism, we aim to revolutionize the management of IBD and help to prevent its associated fibrosis to improve patient outcomes.

With a commitment to innovation, integrity, and patient-centricity, Biogut is driving forward transformative research initiatives that have the potential to reshape the landscape of IBD diagnostics and therapeutics.

IBD & Gut Fibrosis

Our molecular biology RT-PCR based diagnostic on gut biopsy tissue in late-stage development, is intended to serves as a confirmatory test for ulcerative colitis and Crohn’s disease and prediction of progression to fibrosis.

Through diligent and long-term research performed on a particular microbial metabolite receptor, the Biogut research team has been able to identify the physiological role of this receptor in IBD, fibrosis and progression of colorectal cancer. Furthermore, an FDA-approved drug has been identified to work by stimulating this receptor to specifically inhibit the IBD process as well as colorectal cancer proliferation, which can be repurposed.